Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Children with Down syndrome (DS) and acute leukemias acute have unique biological, cytogenetic, and intrinsic factors that affect their treatment and outcome. Myeloid leukemia of Down syndrome (ML-DS) is associated with high event-free survival (EFS) rates and frequently preceded by a preleukemia condition, the transient abnormal hematopoiesis (TAM) present at birth. For acute lymphoblastic leukemia (ALL), their EFS and overall survival are poorer than non-DS ALL, it is important to enroll them on therapeutic trials, including relapse trials; investigate new agents that could potentially improve their leukemia-free survival; and strive to maximize the supportive care these patients need.

Original publication

DOI

10.1016/j.pcl.2014.09.009

Type

Journal article

Journal

Pediatr Clin North Am

Publication Date

02/2015

Volume

62

Pages

121 - 137

Keywords

B-ALL, Down syndrome, GATA1, Leukemia, Myeloid leukemia of Down syndrome, Preleukemia, Transient abnormal hematopoiesis/transient myeloproliferative disorder, Child, Child, Preschool, Down Syndrome, Humans, Leukemia, Mutation, Preleukemia